Resistance to Osimertinib lasts for several years

Osimertinib (Osimertinib) is an oral, irreversible third-generation EGFR-TKI designed to target T790M resistance-associated mutations as well as L858R and exon 19del activating mutations while retaining wild-type EGFR. Osimertinib was initially approved as a second-line treatment for EGFR T790M-positive non-small cell lung cancer based on results from the AURA trial.

According to the results of the FLAURA trial, osimertinib has also been approved as a first-line treatment for advanced EGFR-mutated non-small cell lung cancer. The report showed that untreated patients with EGFR-sensitizing mutations had a progression-free survival (PFS) of 18.9 months and an overall survival (OS) of 38.6 months. Notably, in contrast to earlier EGFR-TKIs, osimertinib can penetrate the brain-blood barrier and exhibit significant central nervous system activity. The resistance time to osimertinib varies from person to person. The specific resistance time depends on the individual differences of the patient, the type of gene mutation, treatment response and other factors. Generally speaking, osimertinib can be taken for a maximum of 3-5 years, but some patients can maintain long-term efficacy.

OsimertinibThe original drug has been launched in China and has been covered by medical insurance. The price of 80mg*30 tablets per box may be around 5,000 yuan, which is relatively expensive. Currently available overseas Osimertinib generics, such as the specifications produced by Bangladesh Pharmaceutical FactoryThe price of each box of 80mg*30 tablets may be more than 800 yuan (the price may fluctuate due to exchange rate effects), which is relatively cheap. Osimertinib generics have basically the same pharmaceutical ingredients as the original drugs sold domestically and abroad. For more drug information and specific prices, please consult Yaode Medical Consultant.